{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:45:57Z","timestamp":1790646357798,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GUP15010"],"award-info":[{"award-number":["GUP15010"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.nmd.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T02:54:07Z","timestamp":1542164047000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR)"],"prefix":"10.1016","volume":"29","author":[{"given":"Gian Luca","family":"Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stancanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-8846","authenticated-orcid":false,"given":"Costanza","family":"Barcellona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Di Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-7826","authenticated-orcid":false,"given":"Giuseppe","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.nmd.2018.11.002_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2018.11.002_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.nmd.2018.11.002_bib0003","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.nmd.2018.11.002_bib0004","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.nmd.2018.11.002_bib0005","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2018.11.002_bib0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nmd.2018.11.002_bib0007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary ransthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.nmd.2018.11.002_bib0008","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2018.11.002_bib0009","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2018.11.002_bib0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2018.11.002_bib0011","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J Neurol"},{"issue":"11-12","key":"10.1016\/j.nmd.2018.11.002_bib0012","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.nmd.2007.08.003","article-title":"Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy","volume":"17","author":"Kierkegaard","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2018.11.002_bib0013","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nmd.2018.11.002_bib0014","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.21544","article-title":"The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy","volume":"41","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2018.11.002_bib0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/16501970410029816","article-title":"Influence of foot pain on walking ability of diabetic patients","volume":"36","author":"Novak","year":"2004","journal-title":"J Rehabil Med"},{"issue":"8","key":"10.1016\/j.nmd.2018.11.002_bib0016","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/ene.13033","article-title":"Novel outcome measures for Charcot-Marie-Tooth disease: validation and reliability of 6-min walk test and StepWatch\u2122 activity monitor and identification of the walking features related to higher quality of life","volume":"23","author":"Padua","year":"2016","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2018.11.002_bib0017","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.14585","article-title":"The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis","volume":"177","author":"Decker","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.nmd.2018.11.002_bib0018","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.14586","article-title":"The six-minute walk test in patients with AL amyloidosis: a single centre case series","volume":"177","author":"Pulido","year":"2017","journal-title":"Br J Haematol"},{"issue":"sup1","key":"10.1016\/j.nmd.2018.11.002_bib0019","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2017.1293516","article-title":"Six-minute walk test (6MWT) in AL amyloidosis - baseline and 12-month follow-up after chemotherapy","volume":"24","author":"Flatman","year":"2017","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.nmd.2018.11.002_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.transproceed.2010.12.025","article-title":"Effects of an exercise training program in physical condition after liver transplantation in familial amyloidotic polyneuropathy: a case report","volume":"43","author":"Tom\u00e1s","year":"2011","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.nmd.2018.11.002_bib0021","doi-asserted-by":"crossref","first-page":"E406","DOI":"10.1111\/j.1399-0012.2011.01436.x","article-title":"Body composition, muscle strength, functional capacity, and physical disability risk in liver transplanted familial amyloidotic polyneuropathy patients","volume":"25","author":"Tom\u00e1s","year":"2011","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.nmd.2018.11.002_bib0022","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/13506129.2017.1374946","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.nmd.2018.11.002_bib0023","series-title":"Amyloid and amyloidosis","first-page":"88","article-title":"Forty years of experience with type I amyloid neuropathy. Review of 483 cases","author":"Coutinho","year":"1980"},{"issue":"24","key":"10.1016\/j.nmd.2018.11.002_bib0024","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.nmd.2018.11.002_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS committee on proficiency standards for clinical pulmonary function laboratories. ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.nmd.2018.11.002_bib0026","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","article-title":"Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease","volume":"16","author":"Murphy","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.nmd.2018.11.002_bib0027","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","article-title":"Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester diabetic neuropathy study cohort","volume":"49","author":"Dyck","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nmd.2018.11.002_bib0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(99)00231-2","article-title":"Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients","volume":"171","author":"Tashima","year":"1999","journal-title":"J Neurol Sci"},{"issue":"12","key":"10.1016\/j.nmd.2018.11.002_bib0029","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s00415-007-0617-5","article-title":"A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy","volume":"254","author":"Denier","year":"2007","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2018.11.002_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40120-014-0023-8","article-title":"Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis","volume":"3","author":"Suhr","year":"2014","journal-title":"Neurol Ther"},{"issue":"13","key":"10.1016\/j.nmd.2018.11.002_bib0031","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.nmd.2018.11.002_bib0032","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13506129.2017.1333956","article-title":"Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis","volume":"24","author":"Cariou","year":"2017","journal-title":"Amyloid"},{"issue":"12","key":"10.1016\/j.nmd.2018.11.002_bib0033","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ehjci\/jeu158","article-title":"The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease","volume":"15","author":"Di Bella","year":"2014","journal-title":"Eur Heart J Cardiovasc Imag"},{"key":"10.1016\/j.nmd.2018.11.002_bib0034","series-title":"Statistical power analysis for the behavioural sciences","author":"Cohen","year":"1977"},{"key":"10.1016\/j.nmd.2018.11.002_bib0035","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.5334\/ijic.65","article-title":"Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research","volume":"2","author":"Middel","year":"2002","journal-title":"Int J Integr Care"},{"key":"10.1016\/j.nmd.2018.11.002_bib0036","first-page":"e72","article-title":"Erratum","volume":"8","author":"Middel","year":"2008","journal-title":"Int J Integr Care"},{"issue":"6","key":"10.1016\/j.nmd.2018.11.002_bib0037","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Trans Res"},{"issue":"2","key":"10.1016\/j.nmd.2018.11.002_bib0038","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plant\u00e9-Bordeneuve","year":"2017","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2018.11.002_bib0039","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/eurheartj\/ehi162","article-title":"Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review","volume":"26","author":"Olsson","year":"2005","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.nmd.2018.11.002_bib0040","doi-asserted-by":"crossref","first-page":"W394","DOI":"10.2214\/AJR.09.3721","article-title":"MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy","volume":"195","author":"Di Bella","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"s2","key":"10.1016\/j.nmd.2018.11.002_bib0041","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.3233\/JND-150091","article-title":"Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area","volume":"2","author":"Mazzeo","year":"2015","journal-title":"J Neuromuscul Dis"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618311064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618311064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:08:00Z","timestamp":1760774880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896618311064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0960896618311064"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2018.11.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR)","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}